The Haematology Department at St. James’s Hospital is the largest in Ireland and includes the National Adult Stem Cell Transplant Centre. There are six consultant haematologists who provide care for patients with general and malignant haematological disorders, including leukaemia, lymphoma and myeloma.
Each of the haematology consultants has had training in all areas of stem cell transplantation but also have areas of special interest as follows:
- Dr. L. Bacon: Acute Lymphoblastic Leukaemia, Lymphoma.
- Prof. Browne: Myeloma, Acute Leukaemia.
- Dr. E. Conneally: Acute Leukaemia, Myeloproliferative Disorders.
- Dr. C. Flynn: Acute Leukaemia, Bone Marrow Failure Syndromes.
- Dr. P. Hayden: Myeloma, Acute Leukaemia, Cryobiology/Apheresis.
- Prof. E. Vandenberghe: Lymphomas and Lymphoproliferative Disorders.
There are three components to the Clinical Haemato-Oncology Service:
The Acute Leukaemia/Stem Cell Transplant Service is based on Denis Burkitt Ward. This is a purpose-built facility with 21 single rooms for patients undergoing stem cell transplantation or treatment for acute leukaemia. There is special air filtering in place to minimise the risk of infection. The unit is managed by a clinical nurse manager along with a staff of stem cell transplantation-trained nurses.
Patients requiring less intensive therapy are admitted to one of two dedicated haemato-oncology wards: Walter Stevenson Ward and Donal Hollywood Ward. Patients with a wide range of haematological conditions such as lymphoma, myeloma or myelodysplasia are cared for on this service.
An increasing amount of treatment for haematological cancers is delivered in the day-ward setting on an intermittent basis over several months. Treatment is administered by trained chemotherapy nurses. Clinical nurse specialists are linked to each service to ensure that patients are fully educated about the management of any side-effects of treatment.
Finally, we encourage enrolment in clinical trials and are supported by an active Clinical Trials Unit. This ensures that patients have early access to new treatment options, which may not yet be licensed for routine use.